Figure 4 from A Comparative Study of Neuroendocrine Heterogeneity in Small Cell Lung Cancer and Neuroblastoma

Abstract

<p>NE score association with members of the Myc oncogene family in SCLC and neuroblastoma. Copy number (<b>A</b>) and RNA expression (<b>B</b>) of Myc family genes in SCLC and neuroblastoma cell lines. Note that although MYC amplification was higher in the high-NE-score SCLC cell lines, its gene expression was higher in the low-NE-score cell lines for both SCLC and neuroblastoma lines. Frequent <i>MYCL</i> loss was found in neuroblastoma because <i>MYCL</i> is located in a frequently deleted region (chromosome 1p) in neuroblastoma. <b>C,</b> NE score versus Myc gene member expression in SCLC studies. “UTSW cell line” is a cell line dataset; “Drapkin_2018” is a PDX dataset; “Rudin_2012,” “George_2015,” “Jiang_2016,” and “Cai_2021” are all patient tumor datasets. NE score versus Myc gene member expression in neuroblastoma cell line datasets (<b>D</b>) and tumor datasets (<b>E</b>). Note that some of the same cell lines were profiled in multiple studies. <b>F,</b> Forest plots visualizing meta-analysis of NE score association with Myc family genes. <i>MYC</i> expression is consistently associated with lower NE scores in SCLC and neuroblastoma samples (left). <i>MYCL</i> expression positively correlates with NE scores in SCLC but not neuroblastoma samples (middle). <i>MYCN</i> expression positively correlates with NE scores in neuroblastoma but not SCLC samples. <b>G,</b> Relationship between <i>MYC</i> copy number and gene expression in neuroblastoma and SCLC cell lines. Note that <i>MYC</i> amplification is only observed in SCLC cell lines. <b>H,</b><i>MYCN</i> gene expression positively correlate with NE scores while controlling for <i>MYCN</i> amplification status in neuroblastoma patient tumors.</p>